RMTG (Regenerative Medical Technology Group) Short-Term Debt & Capital Lease Obligation : $17.84 Mil (As of Mar. 2025)

View and export this data going back to . Start your Free Trial

What is Regenerative Medical Technology Group Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Regenerative Medical Technology Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $17.84 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Regenerative Medical Technology Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $2.22 Mil.

Regenerative Medical Technology Group Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Regenerative Medical Technology Group's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenerative Medical Technology Group Short-Term Debt & Capital Lease Obligation Chart

Regenerative Medical Technology Group Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

0.15

1.78

7.08

15.23

17.84

Regenerative Medical Technology Group Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial															16.32	17.35	17.41	17.84	17.84

Regenerative Medical Technology Group Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Regenerative Medical Technology Group Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Regenerative Medical Technology Group's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Regenerative Medical Technology Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenerative Medical Technology Group Inc (OTCPK:RMTG) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

433 Plaza Real, Suite 275, Boca Raton, FL, USA, 33432

Website

https://www.regenmedtechgroup.com

Regenerative Medical Technology Group Inc operates through its subsidiary. Its focus has been mainly dedicated to its operations serving the markets in the regenerative medicine industry. It believes stem cell therapy is becoming an increasingly effective clinical solution for treating conditions that traditional or conventional medicine only offers within palliative care and pain management. Patients around the world are seeking a natural regenerative alternative without the potential risks and side effects sometimes associated with conventional pharmaceuticals.

Executives

Benito Novas	10 percent owner	433 PLAZA REAL, SUITE 275, BOCA RATON FL 33432
David Eugene Christensen	director, 10 percent owner, officer: President and CEO	433 PLAZA REAL, SUITE 275, BOCA RATON FL 33432
Pereira Melvin Antonio Loria	director, 10 percent owner, officer: CEO, Chairman	RESIDENCIAL HACIENDA EL GREGAL, #24-1 SANCHEZ, CURRIDABAT, SAN JOSE G2 11803